 CONSHOHOCKEN, Pa., July 13, 2021 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension OLE NCT04951219. MAESTRO-NAFLD-1 is an ongoing 52-week 1200 patient Phase 3 non-invasive, multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease NAFLD, presumed NASH. The study is due to complete later this year with measures of safety and efficacy including reduction in imaging and biomarker measures of NASH, as well as the lowering of LDL-cholesterol and other atherogenic lipids. 